Type 2 diabetes and metabolic syndrome in youth — formative SAQs

SAQ 1 — The fourteen-year-old with dark skin at the neck and irregular periods (20 marks, ~15 minutes)

A previously well fourteen-year-old girl presents to the general practitioner with worsening acne, irregular periods every six to eight weeks, and dark velvety skin at the back of her neck that she cannot wash off. Her body mass index is at the 95th percentile, and her mother has type 2 diabetes. A random point-of-care glucose reads 11.8 millimoles per litre, and a subsequent HbA1c is 7.1 percent. [1]

Questions

1. Give the diagnosis, the biochemical criteria that confirm it, and the investigations that distinguish the type. (5 marks) [1]
2. Describe the metabolic cluster findings on examination and explain the mechanism that links them. (4 marks) [7]
3. Outline the stepwise management, naming the lifestyle prescription, the first-line drug and its target dose, and the comorbidity care. (6 marks) [1]
4. Explain why polycystic ovary syndrome belongs to the same condition and how it is managed alongside the diabetes. (5 marks) [6]

Model answer (must-hit)

1. This is type 2 diabetes. Diabetes is confirmed by the random glucose of 11.8 with the subsequent HbA1c of 7.1 percent meeting the diagnostic thresholds (random at least 11.1 with symptoms or HbA1c at least 6.5 percent). The type is distinguished by the islet autoantibody panel — glutamic acid decarboxylase, insulinoma-associated antigen 2, insulin and zinc transporter 8, expected negative — and a C-peptide with simultaneous glucose, expected measurable or high, against the phenotype of obesity, acanthosis and family history. [1]

2. The metabolic cluster findings are acanthosis nigricans at the neck, central obesity with striae, hirsutism and acne, oligomenorrhoea, and hepatomegaly suggesting fatty liver disease. The linking mechanism is insulin resistance with compensatory hyperinsulinaemia: the shared signalling defect produces acanthosis at the skin, ovarian hyperandrogenism, hepatic fat accumulation, dyslipidaemia and hypertension together. [7]

3. The stepwise management begins with structured family-based lifestyle change — nutrition with family involvement, at least 60 minutes per day of activity, screen-time limits and weight management. Metformin is first-line, started at 500 milligrams once daily and titrated to a target of 1500 to 2000 milligrams per day. Comorbidity care addresses the blood pressure, the lipid profile and the fatty liver, with an ACE inhibitor or angiotensin receptor blocker for hypertension and a statin where indicated from age ten. [1]

4. Polycystic ovary syndrome belongs to the same condition because both arise from insulin resistance and hyperinsulinaemia, which drive ovarian androgen production and disrupt ovulation. It is managed alongside the diabetes with the same lifestyle prescription and metformin, plus hormonal contraception for cycle control and hirsutism where indicated. The metabolic and reproductive consequences are addressed together. [6]

SAQ 2 — The thirteen-year-old whose metformin is failing (20 marks, ~15 minutes)

A thirteen-year-old boy diagnosed with type 2 diabetes two years ago has been taking metformin 1000 milligrams twice daily with intermittent lifestyle adherence. His HbA1c has risen from 6.9 percent at diagnosis to 8.6 percent now, his blood pressure is 134 over 88, and his urine albumin-to-creatinine ratio is mildly raised. His father and paternal grandmother both have type 2 diabetes. [10]

Questions

1. Explain why the metformin monotherapy is failing and what the TODAY trial showed about this trajectory. (5 marks) [10]
2. Outline the escalation of pharmacotherapy, naming the next agents, their place in the ladder, and the insulin dosing if it is needed. (6 marks) [1]
3. Describe the complication surveillance and the significance of the raised blood pressure and albuminuria. (5 marks) [11]
4. Discuss the role of the family and the social context in the management plan. (4 marks) [1]

Model answer (must-hit)

1. Metformin monotherapy is failing because beta-cell function in youth-onset type 2 diabetes declines about 15 to 20 percent per year, far faster than in adults. The TODAY trial showed that roughly half of adolescents fail metformin monotherapy within a few years and that glycaemic control deteriorates rapidly without escalation, which is the expected trajectory of the disease rather than an exception. [10]

2. The escalation adds agents that address different parts of the pathophysiology. A long-acting basal insulin at 0.25 to 0.5 units per kilogram per day is added for inadequate control, with metformin continued and escalation to basal-bolus if needed. A GLP-1 receptor agonist such as liraglutide and an SGLT2 inhibitor such as empagliflozin are add-on options from age ten; the DINAMO trial established a meaningful HbA1c reduction for empagliflozin in youth. Metformin is never stopped. [1] [8]

3. Complication surveillance is annual from diagnosis: retinal photography, the urine albumin-to-creatinine ratio, a lipid profile and a blood pressure. The raised blood pressure of 134 over 88 and the mildly raised albuminuria are early nephropathy, which appears faster in type 2 than in type 1 because the disease combines hyperglycaemia with the metabolic cluster. The response is an ACE inhibitor or angiotensin receptor blocker, which lowers blood pressure and protects the kidney, not watchful waiting. [11]

4. The family is both the screening trigger and the unit of treatment, because the father and grandmother share the genetics and the lifestyle. The management plan engages the whole family in the same nutrition and activity prescription, addresses the practical barriers of food security and opportunity, and uses school-based and telehealth support to extend the reach. A plan the family cannot follow will not work, so the social context shapes the prescription. [1]